|
1
|
Lai D, Ma L and Wang F: Fibroblast
activation protein regulates tumor-associated fibroblasts and
epithelial ovarian cancer cells. Int J Oncol. 41:541–550. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Giannoni E, Bianchini F, Calorini L and
Chiarugi P: Cancer associated fibroblasts exploit reactive oxygen
species through a proinflammatory signature leading to epithelial
mesenchymal transition and stemness. Antioxid Redox Signal.
14:2361–2371. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Puré E and Lo A: Can targeting stroma pave
the way to enhanced antitumor immunity and immunotherapy of solid
tumors? Cancer Immunol Res. 4:269–278. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu T, Zhou L, Li D, Andl T and Zhang Y:
Cancer-associated fibroblasts build and secure the tumor
microenvironment. Front Cell Dev Biol. 7:602019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Erez N, Truitt M, Olson P, Arron ST and
Hanahan D: Cancer-associated fibroblasts are activated in incipient
neoplasia to orchestrate tumor-promoting inflammation in an
NF-kappaB-dependent manner. Cancer Cell. 17:135–147. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ohshio Y, Teramoto K, Hanaoka J, Tezuka N,
Itoh Y, Asai T, Daigo Y and Ogasawara K: Cancer-associated
fibroblast-targeted strategy enhances antitumor immune responses in
dendritic cell-based vaccine. Cancer Sci. 106:134–142. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Barron DA and Rowley DR: The reactive
stroma microenvironment and prostate cancer progression. Endocr
Relat Cancer. 19:R187–R204. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gascard P and Tlsty TD:
Carcinoma-associated fibroblasts: Orchestrating the composition of
malignancy. Genes Dev. 30:1002–1019. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Valkenburg KC, de Groot AE and Pienta KJ:
Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin
Oncol. 15:366–381. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Elenbaas B and Weinberg RA: Heterotypic
signaling between epithelial tumor cells and fibroblasts in
carcinoma formation. Exp Cell Res. 264:169–184. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xing F, Saidou J and Watabe K: Cancer
associated fibroblasts (CAFs) in tumor microenvironment. Front
Biosci (Landmark Ed). 15:166–179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bhowmick NA, Neilson EG and Moses HL:
Stromal fibroblasts in cancer initiation and progression. Nature.
432:332–337. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Santos AM, Jung J, Aziz N, Kissil JL and
Puré E: Targeting fibroblast activation protein inhibits tumor
stromagenesis and growth in mice. J Clin Invest. 119:3613–3625.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Edosada CY, Quan C, Tran T, Pham V,
Wiesmann C, Fairbrother W and Wolf BB: Peptide substrate profiling
defines fibroblast activation protein as an endopeptidase of strict
Gly(2)-Pro(1)-cleaving specificity. FEBS Lett. 580:1581–1586. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Edosada CY, Quan C, Wiesmann C, Tran T,
Sutherlin D, Reynolds M, Elliott JM, Raab H, Fairbrother W and Wolf
BB: Selective inhibition of fibroblast activation protein protease
based on dipeptide substrate specificity. J Biol Chem.
281:7437–7444. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jansen K, Heirbaut L, Cheng JD, Joossens
J, Ryabtsova O, Cos P, Maes L, Lambeir AM, De Meester I, Augustyns
K, et al: Selective inhibitors of fibroblast activation protein
(FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold.
ACS Med Chem Lett. 4:491–496. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Meadows SA, Edosada CY, Mayeda M, Tran T,
Quan C, Raab H, Wiesmann C and Wolf BB: Ala657 and conserved active
site residues promote fibroblast activation protein endopeptidase
activity via distinct mechanisms of transition state stabilization.
Biochemistry. 46:4598–4605. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ostermann E, Garin-Chesa P, Heider KH,
Kalat M, Lamche H, Puri C, Kerjaschki D, Rettig WJ and Adolf GR:
Effective immunoconjugate therapy in cancer models targeting a
serine protease of tumor fibroblasts. Clin Cancer Res.
14:4584–4592. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jia J, Martin TA, Ye L and Jiang WG: FAP-α
(Fibroblast activation protein-α) is involved in the control of
human breast cancer cell line growth and motility via the FAK
pathway. BMC Cell Biol. 15:162014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nyberg-Hoffman C, Shabram P, Li W, Giroux
D and Aguilar-Cordova E: Sensitivity and reproducibility in
adenoviral infectious titer determination. Nat Med. 3:808–811.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xie J, Xiong L, Tao X, Li X, Su Y, Hou X
and Shi H: Antitumor effects of murine bone marrow-derived
dendritic cells infected with xenogeneic livin alpha recombinant
adenoviral vectors against lewis lung carcinoma. Lung Cancer.
68:338–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee J, Fassnacht M, Nair S, Boczkowski D
and Gilboa E: Tumor immunotherapy targeting fibroblast activation
protein, a product expressed in tumor-associated fibroblasts.
Cancer Res. 65:11156–11163. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Puré E and Blomberg R: Pro-tumorigenic
roles of fibroblast activation protein in cancer: Back to the
basics. Oncogene. 37:4343–4357. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
van der Bruggen P, Traversari C, Chomez P,
Lurquin C, De Plaen E, Van den Eynde B, Knuth A and Boon T: A gene
encoding an antigen recognized by cytolytic T lymphocytes on a
human melanoma. Science. 254:1643–1647. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Willimsky G, Czéh M, Loddenkemper C,
Gellermann J, Schmidt K, Wust P, Stein H and Blankenstein T:
Immunogenicity of premalignant lesions is the primary cause of
general cytotoxic T lymphocyte unresponsiveness. J Exp Med.
205:1687–1700. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dunn GP, Koebel CM and Schreiber RD:
Interferons, immunity and cancer immunoediting. Nat Rev Immunol.
6:836–848. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Speiser DE, Baumgaertner P, Barbey C,
Rubio-Godoy V, Moulin A, Corthesy P, Devevre E, Dietrich PY,
Rimoldi D, Liénard D, et al: A novel approach to characterize
clonality and differentiation of human melanoma-specific T cell
responses: Spontaneous priming and efficient boosting by
vaccination. J Immunol. 177:1338–1348. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rosenberg SA, Sherry RM, Morton KE,
Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo
NP, Hughes MS, et al: Tumor progression can occur despite the
induction of very high levels of self/tumor antigen-specific CD8 +
T cells in patients with melanoma. J Immunol. 175:6169–6176. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Valmori D, Souleimanian NE, Tosello V,
Bhardwaj N, Adams S, O'Neill D, Pavlick A, Escalon JB, Cruz CM,
Angiulli A, et al: Vaccination with NY-ESO-1 protein and CpG in
montanide induces integrated antibody/Th1 responses and CD8 T cells
through cross-priming. Proc Natl Acad Sci USA. 104:8947–8952. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Garin-Chesa P, Old LJ and Rettig WJ: Cell
surface glycoprotein of reactive stromal fibroblasts as a potential
antibody target in human epithelial cancers. Proc Natl Acad Sci
USA. 87:7235–7239. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dolznig H, Schweifer N, Puri C, Kraut N,
Rettig WJ, Kerjaschki D and Garin-Chesa P: Characterization of
cancer stroma markers: In silico analysis of an mRNA expression
database for fibroblast activation protein and endosialin. Cancer
Immun. 5:102005.PubMed/NCBI
|
|
32
|
Scarfò I and Maus MV: Current approaches
to increase CAR T cell potency in solid tumors: Targeting the tumor
microenvironment. J Immunother Cancer. 5:282017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Orimo A, Gupta PB, Sgroi DC,
Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL
and Weinberg RA: Stromal fibroblasts present in invasive human
breast carcinomas promote tumor growth and angiogenesis through
elevated SDF-1/CXCL12 secretion. Cell. 121:335–348. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen WT and Kelly T: Seprase complexes in
cellular invasiveness. Cancer Metastasis Rev. 22:259–269. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rosenblum JS and Kozarich JW: Prolyl
peptidases: A serine protease subfamily with high potential for
drug discovery. Curr Opin Chem Biol. 7:496–504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hofheinz RD, al-Batran SE, Hartmann F,
Hartung G, Jäger D, Renner C, Tanswell P, Kunz U, Amelsberg A,
Kuthan H and Stehle G: Stromal antigen targeting by a humanised
monoclonal antibody: An early phase II trial of sibrotuzumab in
patients with metastatic colorectal cancer. Onkologie. 26:44–48.
2003.PubMed/NCBI
|
|
37
|
Scott AM, Wiseman G, Welt S, Adjei A, Lee
FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, et al: A
phase I dose-escalation study of sibrotuzumab in patients with
advanced or metastatic fibroblast activation protein-positive
cancer. Clin Cancer Res. 9:1639–1647. 2003.PubMed/NCBI
|
|
38
|
Kawase T, Yasui Y, Nishina S, Hara Y,
Yanatori I, Tomiyama Y, Nakashima Y, Yoshida K, Kishi F, Nakamura M
and Hino K: Fibroblast activation protein-α-expressing fibroblasts
promote the progression of pancreatic ductal adenocarcinoma. BMC
Gastroenterol. 15:1092015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Brennen WN, Rosen DM, Wang H, Isaacs JT
and Denmeade SR: Targeting carcinoma-associated fibroblasts within
the tumor stroma with a fibroblast activation protein-activated
prodrug. J Natl Cancer Inst. 104:1320–1334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schreiber H and Rowley DA: Cancer.
Awakening immunity. Science. 330:761–762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kraman M, Bambrough PJ, Arnold JN, Roberts
EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA and Fearon DT:
Suppression of antitumor immunity by stromal cells expressing
fibroblast activation protein-alpha. Science. 330:827–830. 2010.
View Article : Google Scholar : PubMed/NCBI
|
